Above the Pill: Why you should engage with customers before they're your customers

AJMC is proud to bring you an educational webinar that will provide reasons & examples on why you should engage with customers before they\'re your customers.

Related Videos

Related Content

Advertisement

July 18th 2025

Analysis Highlights Comparative Efficacy of Alopecia Areata Drugs

Jared Kaltwasser

Investigators found that Janus kinase inhibitors were effective in a dose-dependent manner.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 18th 2025

Racial Disparities Persist in Retention in Care for HIV

Julia Bonavitacola

HIV care and its related outcomes in South Carolina were defined by racial disparities, specifically in retention in care, despite efforts to end the HIV epidemic.

July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi

Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.

July 18th 2025

FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL

Maggie L. Shaw

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

July 18th 2025

Ruxolitinib Shows Sustained Clinical, QOL Benefits in Real-World Data

Rose McNulty

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.

Related Content

Advertisement

July 18th 2025

Analysis Highlights Comparative Efficacy of Alopecia Areata Drugs

Jared Kaltwasser

Investigators found that Janus kinase inhibitors were effective in a dose-dependent manner.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

July 18th 2025

Racial Disparities Persist in Retention in Care for HIV

Julia Bonavitacola

HIV care and its related outcomes in South Carolina were defined by racial disparities, specifically in retention in care, despite efforts to end the HIV epidemic.

July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi

Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.

July 18th 2025

FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL

Maggie L. Shaw

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

July 18th 2025

Ruxolitinib Shows Sustained Clinical, QOL Benefits in Real-World Data

Rose McNulty

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.